FHTX (Foghorn Therapeutics) Research & Development: $78.83 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FHTX Foghorn Therapeutics Inc FHTX
67 GF Score
Price $6.69
GF Value $5.32
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Foghorn Therapeutics Research & Development?

Foghorn Therapeutics FHTX -2.19% 67 Research & Development is $78.83 Mil as of Jun. 2026. GuruFocus rates FHTX with a GF Score™ of 67/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Foghorn Therapeutics's Research & Development for the three months ended in Jun. 2026 was $18.52 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was $78.83 Mil.

Foghorn Therapeutics  (NAS:FHTX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Foghorn Therapeutics Research & Development Related Terms

Foghorn Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Foghorn Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foghorn Therapeutics Research & Development Chart

Foghorn Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 80.33 105.62 109.69 94.53 85.47

Foghorn Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.79 20.00 22.05 18.26 18.52
FHTX
67GF Score
Foghorn Therapeutics Inc FHTX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Foghorn Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $78.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $78.83 Mil mean?
Foghorn Therapeutics (FHTX) has a Research & Development of $78.83 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Foghorn Therapeutics and its competitors.
Is Foghorn Therapeutics' Research & Development too high?
Foghorn Therapeutics' current Research & Development is $78.83 Mil. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' Research & Development compare to NWBO and FATE?
Foghorn Therapeutics' Research & Development of $78.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Foghorn Therapeutics and its competitors. Foghorn Therapeutics's current Research & Development is $78.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.69 — trading 25.8% above its estimated fair value. The current Research & Development is $78.83 Mil. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current Research & Development is $78.83 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Foghorn Therapeutics (FHTX) Overvalued in 2026?

Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued. The current stock price of $6.69 is trading 25.8% above its estimated GF Value™ of $5.32. GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.

Key valuation signals for FHTX:

  • Research & Development: $78.83 Mil
  • GF Value™: $5.32 vs. price of $6.69 (25.8% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Foghorn Therapeutics Business Description

Address 99 Coolidge Avenue, Suite 500, Watertown, MA, USA, 02472
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score

Get the complete analysis for FHTX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.69
Price
$5.32
GF Value